TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157)
Health Care · Biotechnology · TW
NT$9.33
+7.86% today · +6.0% 1Y
TaiGen Biopharmaceuticals Holdings Limited (TPEX: 4157) operates in the Biotechnology industry within the Health Care sector. The company is valued at $207.71M and employs 52 people.
Over the last twelve months the share price has gained 6.0%, trading between 7.73 and 16.40.
Tweenvest scores TaiGen Biopharmaceuticals Holdings Limited across four factors: quality 61/100, value 24/100, growth 100/100. Its strongest factor is growth.
4157 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $207.71M
- Revenue (TTM)
- $8.06M
- P/E
- 44.08
- EPS
- 0.21
- Dividend yield
- —
- Beta (5Y)
- 0.23
- 52-week high
- NT$16.40
- 52-week low
- NT$7.73
- Avg volume (3M)
- —
- Shares outstanding
- 711.83M
- Employees
- 52
- Next earnings
- —
About TaiGen Biopharmaceuticals Holdings Limited
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
- ISIN
- KYG866171005
- Founded
- 2001
- Listed since
- Aug 30, 2013
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Genome & CompanyKOSDAQ: A314130 | $212.80M | ₩5,470.00 | -0.55% |
| Invivyd, Inc.NasdaqGM: IVVD | $212.58M | $0.67 | -6.64% |
| Guangzhou Innogen Pharmaceutical Group Co., LtdSEHK: 2591 | $209.56M | HK$3.60 | -3.49% |
| HLB Therapeutics Co.,Ltd.KOSDAQ: A115450 | $208.16M | ₩3,175.00 | +28.54% |
| Genomictree Inc.KOSDAQ: A228760 | $206.67M | ₩11,320.00 | -7.21% |
| Shanghai Rightongene Biotechnology Co., Ltd.SHSE: 688217 | $204.58M | CN¥24.83 | -3.20% |
| Anbio BiotechnologyNasdaqGM: NNNN | $204.53M | $4.41 | -5.36% |
| Entrada Therapeutics, Inc.NasdaqGM: TRDA | $204.44M | $5.50 | -3.00% |
Figures last refreshed Oct 11, 2026.